Shorted
Resmed logo
RMD

Resmed

Health Care Equipment & Services

ResMed is a global leader in the design, manufacture, and distribution of medical devices and cloud-based software solutions that diagnose, treat, and manage respiratory disorders, including sleep apnea, COPD, and other chronic diseases. The company's core business revolves around providing innovative solutions for improving the quality of life for people with respiratory conditions, holding a significant market share in the sleep apnea treatment market.

Short position

short percentage0.44%
reported shorts2.5M
shares on issue570.128M

Resmed (ASX:RMD) has 0.44% of its shares on issue reported as short positions as of 5 Oct 2026, or about 2,484,851 shares. Over the past 30 days that figure has fallen 0.12 percentage points, and over 90 days it has risen 0.08 percentage points. Its highest recorded short interest was 3.10% in October 2014. RMD is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Resmed (RMD) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
20h ago

Why Is ResMed (ASX:RMD) Leaning on Capital Returns?

Highlights The sleep-apnoea device maker plans a large share repurchase and a higher dividend for the new financial year. A business sale closed last month, freeing cash to fund an accelerated repurchase. Quarterly earnings due in late October will show how demand and margins are tracking. ResMed (ASX:RMD), the sleep and respiratory care device maker that lists on both the New York and Australian exchanges, has laid out a heavy capital return plan for the new financial year, combining a large...

Continue reading
Kalkine
Positive
1 Oct

Will ResMed (ASX:RMD) stay a fund manager favourite?

Highlights Weekend sector coverage noted fund managers running overweight positions in ResMed as money flows back into large healthcare names. The sleep apnoea device maker has been rebuilding after a soft outlook for the new financial year knocked its shares in August. A rating upgrade, an accelerated capital return and competitor setbacks support the bullish side of the debate. ResMed (ASX:RMD) is drawing renewed attention this week after sector coverage highlighted that local fund managers...

Continue reading
Kalkine
Neutral
28 Sept

How is ResMed (ASX:RMD) placed as the dollar and yields shift?

Highlights The sleep and breathing health group is working through an accelerated share repurchase funded partly by an asset sale. New clinical research presented in Europe this month strengthened the case for sustained therapy use. Earnings are generated largely in US dollars, tying the local listing closely to currency moves. ResMed (ASX:RMD) begins the week as a US-anchored healthcare heavyweight on the local market, with its accelerated share repurchase under way, fresh clinical data from...

Continue reading
Kalkine
Neutral
25 Sept

Will ResMed (ASX:RMD) Keep Taking Share in Sleep Apnoea?

Highlights Sleep device leader drew a fresh upgrade from a Canadian bank Rival setbacks underpin the market share argument Softer sales outlook still weighs on sentiment ResMed (ASX:RMD) is back in focus this week as the market weighs a fresh upgrade from a major Canadian bank, which argues that competitor setbacks leave the sleep apnoea device leader well placed to keep winning share, against a softer sales outlook that knocked the stock last month. The Upgrade Case RBC Capital Markets lifte...

Continue reading
Kalkine
Neutral
24 Sept

What Is ResMed Signalling With Its Share Repurchase (ASX:RMD)?

Highlights ResMed is running a sizeable accelerated share repurchase funded by the sale of its MatrixCare business and cash on hand. The repurchase was built into guidance for the current financial year and is scheduled to settle by December. New research presented in Europe this month linked longer nightly therapy use with lower mortality risk in sleep apnoea patients. ResMed (ASX:RMD) is in focus today as its accelerated share repurchase moves towards settlement and new clinical research pr...

Continue reading
Kalkine
Neutral
22 Sept

Why Could ResMed (ASX:RMD) Anchor Healthcare Stocks?

Highlights ResMed (ASX:RMD) designs and manufactures medical devices for sleep apnea and respiratory care. Its global distribution network supports its position among Healthcare Stocks. Product innovation and healthcare provider relationships remain central to its performance. Sleep and respiratory health continue to be significant areas of global healthcare focus, and ResMed (ASX:RMD) remains one of the largest names addressing that space. Sitting within Healthcare Stocks, the company's glob...

Continue reading
Kalkine
Neutral
15 Sept

Why Could ResMed (ASX:RMD) Stand Out as Markets Turn Defensive?

Highlights ResMed enters the September session with defensive growth attracting renewed attention amid a volatile Australian market backdrop. Higher bond yields, elevated commodity prices and shifting sector leadership are reshaping how healthcare stocks are viewed. ResMeds sleep and respiratory care focus gives the company a distinct set of operating, valuation and market sensitivities. The Australian sharemarket is facing a more complicated September setup, with commodity markets, bond...

Continue reading
Kalkine
Neutral
11 Sept

Is ResMed (ASX:RMD) the Steadier Name in Healthcare?

Highlights New sleep apnoea research was presented at a European respiratory congress this month. Weight management therapies are being framed as a tailwind rather than a threat. Recurring mask and accessory resupply remains the most predictable revenue stream. ResMed (ASX:RMD) entered a punishing week for local healthcare with a rare advantage over its sector peers, namely an operating story that has been improving rather than deteriorating. The sleep and respiratory device maker presented n...

Continue reading
Kalkine
Positive
10 Sept

ResMed (ASX:RMD): What supports care growth?

Highlights Resmed has a fresh disclosure linked to device innovation, digital adherence and operating leverage. Sleep devices, masks and connected home care software remain central to the operating assessment. Execution, cash discipline and disclosure continuity remain the clearest markers. [ASX 100] Resmed (ASX:RMD) is back in focus after recent annual results showed revenue growth and continued cash returns. The timely update directs attention to sleep devices, masks and connected home care...

Continue reading
Kalkine
Neutral
31 Aug

ResMed (ASX:RMD): Is Its Value Story Changing?

Highlights ResMeds share price has faced pressure in 2026, bringing valuation metrics back into focus across the Australian share market. Strong revenue growth, expanding profitability and a cash-rich balance sheet remain key features of the medical equipment group. Its price-to-sales valuation sits below its longer-term historical average, adding a fresh dimension to the debate around its current value. The Australian share market has seen renewed attention on established healthcare companies...

Continue reading
Kalkine
Neutral
27 Aug

Why Is ResMed (ASX:RMD) Driving Healthcare Attention?

Highlights ResMed is drawing attention as connected care delivered at home becomes more important to the Australian market conversation. The companys position across sleep and respiratory care devices, masks, software and connected patient-support tools gives readers a practical lens on changing conditions in medical devices and digital health. Operational delivery, capital discipline and clear strategic priorities remain central as the sector continues evolving. Australias sharemarket is ent...

Continue reading
Kalkine
Positive
23 Aug

What Does ResMed’s (ASX:RMD) Dividend Update Mean for CDI Holders?

Highlights ResMed (ASX:RMD) has updated its dividend notification for holders of CHESS Depositary Interests on the Australian Securities Exchange. The announcement clarifies the foreign exchange mechanism used to translate the distribution for Australian CDI holders. Cross-border withholding tax treatment remains an important consideration for eligible Australian investors receiving ResMed distributions. ResMed (ASX:RMD) has provided Australian investors with an updated dividend notification c...

Continue reading
Kalkine
Neutral
21 Aug

Can ResMed (ASX:RMD) Reshape the Healthcare Outlook?

Highlights ResMed is being assessed through demand durability, product adoption and the quality of execution rather than short-term market direction. The healthcare stocks backdrop makes margin quality and research investment especially useful when separating company evidence from sector noise. Upcoming disclosures can clarify whether global execution is supporting or constraining the operating story around ResMed. Reporting-season volatility has sharpened the divide between narrative and exe...

Continue reading
Kalkine
Neutral
20 Aug

ResMed (ASX:RMD): Why does All Ordinaries context matter?

Highlights For ResMed, the All Ordinaries backdrop is useful only as a comparison point; the stronger evidence comes from how research intensity feeds into market penetration. ResMed is approached from the quality of execution quality, not from a broad market-direction call. The analysis works backwards from market penetration to test what research intensity is actually saying about the business. That company-first framing keeps the All Ordinaries reference useful without allowing the index to ...

Continue reading
Kalkine
Neutral
19 Aug

ResMed (ASX:RMD) Catalyst Watch: What Could Move Shares Next on 19 August

Highlights The 19 August reporting calendar includes ARB Corporation, Bega Cheese, Breville Group, BWP Trust and Deterra Royalties among companies scheduled to report. ResMed (ASX:RMD) is the primary company lens, while CSL (ASX:CSL), Cochlear (ASX:COH), Pro Medicus (ASX:PME) provide category context. The article focuses on earnings quality, product demand and healthcare growth durability without using directional investment recommendations. The central question for healthcare stocks is no lo...

Continue reading
Kalkine
Neutral
19 Aug

Why Does ResMed (ASX:RMD) Matter Today?

Highlights ResMed remains closely watched as sleep and respiratory care devices, software and patient access shapes its place within Australia's healthcare stocks landscape. Operational delivery, capital discipline and clear disclosure remain central to how the company's progress is assessed. Broader demand linked to ageing populations, improved diagnosis and demand for effective treatment pathways continues influencing the sector conversation. Australia's sharemarket is moving through an act...

Continue reading
Kalkine
Positive
18 Aug

ResMed Lifts Dividend But Shares Slide On Caution (ASX:RMD)

Highlights ResMed delivered a solid full-year result with revenue in line with expectations and a lift to its dividend. Despite the steady numbers, shares slid sharply as the market focused on the coming year's forward outlook. Lingering competitive and weight-loss drug related questions continue to shape sentiment toward the sleep therapy leader. ResMed (ASX:RMD) delivered a full-year result broadly in line with expectations and lifted its dividend by a healthy margin, yet the stock slid sha...

Continue reading
Kalkine
Neutral
17 Aug

ResMed (ASX:RMD) Steadies After Its Latest Update

Highlights Device and mask revenue growth outpaced the wider medical technology group this reporting stretch. Gross margin expansion came despite persistent freight and component cost pressure. Software and residential care services now form a distinct part of the revenue mix. ResMed (ASX:RMD), the dual-listed sleep and respiratory device manufacturer with its operational base in San Diego and a long-standing Australian listing, steadied through the past week after delivering a closing-period...

Continue reading
Kalkine
Neutral
17 Aug

What Is ResMed (ASX:RMD) Revealing About Healthcare?

Highlights ResMed is viewed through clinical demand, product adoption and service volumes, keeping the discussion anchored to company-specific operating evidence. The Healthcare Stocks lens is used only as context; the article separates ResMed's business model from broader sector shorthand. Fresh disclosures around regulatory pathway, capacity utilisation and international reach are the most useful checkpoints for judging how the narrative is evolving. For Australian shares, the more useful s...

Continue reading
Kalkine
Neutral
13 Aug

Why ResMed (ASX:RMD) Could Be Worth Watching in Midcap Stocks Now?

Highlights Attention on ResMed is shifting from broad headlines toward the mechanics of the business. The current midcap stocks discussion includes market share, operating leverage and competitive positioning. A clearer market narrative depends on consistent evidence across demand, delivery and financial flexibility. Australian equities are moving through a period in which sector labels alone explain less than they once did. ResMed (ASX:RMD) is being viewed through a sharper operating lens, w...

Continue reading
Kalkine
Neutral
7 Aug

ResMed Inc. (ASX:RMD): Why Is Value Back in Focus?

Highlights ResMed combines global sleep and breathing health demand with a recurring device, mask and digital-care ecosystem. Recent operating momentum has been supported by stronger demand, manufacturing efficiency and improved gross-margin performance. The valuation discussion increasingly centres on earnings durability, cash generation and whether operational progress can support a more balanced market assessment. Australian healthcare shares remain under close scrutiny as the market reass...

Continue reading
Kalkine
Neutral
3 Aug

ResMed (ASX:RMD): Can Operating Delivery Change the Story?

Highlights ResMed enters the reporting period with device demand and gross margin central to the next company disclosure and the wider market debate. The Healthcare Stocks backdrop is testing volumes, reimbursement and operating margins as rates, demand and capital discipline shape market interpretation. A comparison with Fisher & Paykel Healthcare clarifies differences in scale, operating exposure, funding needs and sensitivity to external conditions. Local equities move into the current ...

Continue reading
Kalkine
Neutral
29 July

What Makes ResMed (ASX:RMD) a Health Signal?

Highlights ResMed is drawing attention as sleep health strength helping the sector's rebound. Today's ASX tone is shaped by large healthcare names are regaining attention as rate fear cools. The key question is whether recurring device demand can offset broad sector nerves. A: ustralia's sharemarket has opened with a firmer pulse, and CSL (ASX:CSL), a global biotechnology company with blood products and vaccines exposure, is helping frame why ResMed matters to the latest conversation around h...

Continue reading
Kalkine
Neutral
22 July

ResMed Sharpens Focus With Software Arm Sale

Highlights A respiratory-care leader has agreed to offload a US healthcare software business at a healthy gain. The divestment lets the company lean harder into its core sleep and breathing franchise. The move underscores a broader push across medical-device names to streamline their portfolios. Portfolio housekeeping rarely grabs headlines, but a fresh divestment has put one of the market's most globally recognised device makers back in the conversation. ResMed (ASX:RMD), the sleep-apnoea an...

Continue reading
Kalkine
Neutral
21 July

How Does ResMed (ASX:RMD) Anchor the Health Mid-Cap Revival?

Highlights A sleep and breathing device maker anchored a broader recovery in health mid caps. Steady demand for treatment of sleep apnoea underpins a resilient, recurring revenue base. The sector rebounded firmly after a bruising stretch earlier in the financial year. A recovery in Australian health stocks gathered pace this month, with a global sleep and breathing device maker anchoring the turn. ResMed (ASX:RMD), a medical technology company that designs devices and software to treat sleep ...

Continue reading
Kalkine
Neutral
21 July

ASX health mid caps revive as ResMed (ASX:RMD) steadies

Highlights A sleep and breathing device maker anchored a broader recovery in health mid caps. Steady demand for treatment of sleep apnoea underpins a resilient, recurring revenue base. The sector rebounded firmly after a bruising stretch earlier in the financial year. A recovery in Australian health stocks gathered pace this month, with a global sleep and breathing device maker anchoring the turn. ResMed (ASX:RMD), a medical technology company that designs devices and software to treat sleep ap...

Continue reading